Nicolas Guzman
Overview
Explore the profile of Nicolas Guzman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fishbane S, Jadoul M, Dember L, Kovesdy C, Al-Shurbaji A, Lisovskaja V, et al.
BMJ Open
. 2023 May;
13(5):e071309.
PMID: 37230521
Introduction: Patients with kidney failure receiving chronic haemodialysis have elevated risk of arrhythmias potentially increasing the likelihood of sudden cardiac death, stroke and hospitalisation. The DIALIZE study (NCT03303521) demonstrated that...
2.
Spinowitz B, Fishbane S, Fukagawa M, Ford M, Guzman N, Rastogi A
Int J Nephrol
. 2022 May;
2022:6304571.
PMID: 35531468
Background: Evidence of longitudinal serum potassium (sK) concentrations in hyperkalemic hemodialysis patients is sparse. Objective: These post hoc analyses of the placebo arm of the phase 3b DIALIZE study (NCT03303521)...
3.
Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, et al.
Kidney Int Rep
. 2022 May;
7(4):908-912.
PMID: 35497779
No abstract available.
4.
Grandy S, Palaka E, Guzman N, Dunn A, Wittbrodt E, Finkelstein F
J Patient Exp
. 2022 Apr;
9:23743735221092629.
PMID: 35425851
Anemia in chronic kidney disease (CKD) is associated with reduced health-related quality of life and physical functioning. This study investigated knowledge and awareness of anemia in patients with CKD in...
5.
Fishbane S, Pollock C, El-Shahawy M, Escudero E, Rastogi A, Pham Van B, et al.
J Am Soc Nephrol
. 2022 Apr;
33(4):850-866.
PMID: 35361724
Background: Concerns regarding cardiovascular safety with current treatments for anemia in patients with dialysis-dependent (DD)-CKD have encouraged the development of alternatives. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates...
6.
Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, et al.
BMC Nephrol
. 2022 Feb;
23(1):59.
PMID: 35135481
Background: Sodium zirconium cyclosilicate (SZC) is an effective and well-tolerated treatment for hyperkalemia in maintenance hemodialysis patients. In post-hoc analyses of the phase 3b DIALIZE study, we examined the spectrum...
7.
Spinowitz B, McCafferty K, Fishbane S, Fukagawa M, Guzman N, Ford M, et al.
Hemodial Int
. 2021 Dec;
26(2):274-277.
PMID: 34927340
No abstract available.
8.
Ford M, Fishbane S, Spinowitz B, Rastogi A, Guzman N, McCafferty K
Kidney Int Rep
. 2021 Dec;
6(12):3074-3078.
PMID: 34901576
No abstract available.
9.
Hao C, Wittbrodt E, Palaka E, Guzman N, Dunn A, Grandy S
Int J Nephrol Renovasc Dis
. 2021 Mar;
14:53-64.
PMID: 33654421
Background: Anemia is a common complication of chronic kidney disease (CKD) that may reduce patients' health-related quality of life (HRQoL). This study explored the experience and knowledge of patients with...
10.
Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, et al.
J Am Soc Nephrol
. 2019 Jun;
30(9):1723-1733.
PMID: 31201218
Background: Patients with ESRD have minimal renal potassium excretion and, despite hemodialysis, often have persistent predialysis hyperkalemia. The DIALIZE study (NCT03303521) evaluated sodium zirconium cyclosilicate (SZC) in the management of...